#1 Clinical Trials Search in Europe

Emtricitabine

Emtricitabine, a nucleoside reverse transcriptase inhibitor, is being studied in various clinical trials for its effectiveness in treating HIV, hepatitis B, and potentially Alzheimer’s disease. These trials aim to evaluate the drug’s safety, efficacy, and potential new applications across different patient populations, including adults, children, and pregnant women.

Table of Contents

What is Emtricitabine?

Emtricitabine, also known as FTC, is an antiretroviral medication primarily used in the treatment of HIV (Human Immunodeficiency Virus) infections[1]. It belongs to a class of drugs called nucleoside reverse transcriptase inhibitors (NRTIs). Emtricitabine is often marketed under brand names such as Emtriva or Huierding[2].

Uses of Emtricitabine

Emtricitabine is primarily used for:

  • HIV Treatment: It is a key component in many antiretroviral therapy regimens for treating HIV infections[3].
  • HIV Prevention: It is used as part of pre-exposure prophylaxis (PrEP) to prevent HIV infection in high-risk individuals[4].
  • Hepatitis B Treatment: Some studies have explored its use in treating chronic hepatitis B infections[2].

How Emtricitabine Works

Emtricitabine works by inhibiting the reverse transcriptase enzyme of HIV and hepatitis B virus. This enzyme is crucial for the viruses to replicate their genetic material. By blocking this process, emtricitabine helps to reduce the amount of virus in the body, which is often referred to as the viral load[1].

Emtricitabine in Combination Therapies

Emtricitabine is rarely used alone. It is typically combined with other antiretroviral drugs to create more effective treatment regimens. Some common combinations include:

  • Truvada: A combination of emtricitabine and tenofovir, used for both HIV treatment and prevention[4].
  • Atripla: A combination of efavirenz, emtricitabine, and tenofovir[5].
  • Eviplera (also known as Complera): A combination of rilpivirine, emtricitabine, and tenofovir[3][5].

Emtricitabine for Different Patient Groups

Research has been conducted on the use of emtricitabine in various patient populations:

  • Pediatric Patients: Studies have explored the safety and efficacy of emtricitabine in HIV-infected children and adolescents[1].
  • Pregnant Women: Research has been conducted on the use of emtricitabine in pregnant women with chronic hepatitis B to prevent mother-to-child transmission[6].
  • Adults with HIV and Hepatitis B Co-infection: Some studies have investigated the use of emtricitabine in patients with both HIV and hepatitis B[7].

Potential Side Effects

Like all medications, emtricitabine can cause side effects. Common side effects may include:

  • Headache
  • Diarrhea
  • Nausea
  • Rash
  • Fatigue

More serious side effects can occur but are less common. It’s important to discuss potential side effects with your healthcare provider[4].

Ongoing Research

Researchers continue to study emtricitabine for potential new uses and to better understand its long-term effects. Some areas of ongoing research include:

  • Lipid Profile Changes: Studies are investigating how switching between different emtricitabine-containing regimens might affect patients’ lipid profiles (the levels of different fats in the blood)[5].
  • Alzheimer’s Disease: Interestingly, some researchers are exploring whether emtricitabine might have potential in treating Alzheimer’s disease, based on its anti-inflammatory properties[8].
Aspect Details
Conditions Studied HIV-1 infection, Chronic Hepatitis B, Alzheimer’s disease
Patient Populations Adults, children, pregnant women
Dosage Forms Oral capsules, oral solution
Common Dosages 200 mg daily for adults, 6 mg/kg for children (max 200-240 mg)
Combination Therapies Often combined with other antiretrovirals (e.g., tenofovir, efavirenz, rilpivirine)
Primary Outcomes Viral suppression, safety and tolerability, prevention of vertical transmission
Secondary Outcomes Changes in CD4+ counts, ALT normalization, HBeAg loss/seroconversion, cognitive function changes
Safety Monitoring Adverse events, laboratory toxicities, birth defects in newborns of treated mothers
Novel Applications Potential use in Alzheimer’s disease treatment
Study Durations Vary from 48 weeks to 96 weeks, with some extending to post-delivery follow-ups

FAQ

  • What conditions is emtricitabine being studied for in clinical trials? Emtricitabine is being studied for HIV-1 infections, chronic hepatitis B, and potentially Alzheimer's disease. It is being tested in various patient groups, including adults, children, and pregnant women.
  • How is emtricitabine being used in HIV treatment trials? In HIV treatment trials, emtricitabine is often used in combination with other antiretroviral drugs. For example, it's being studied as part of combination therapies like Atripla (efavirenz + emtricitabine + tenofovir) and Eviplera (rilpivirine + emtricitabine + tenofovir) to assess their effects on viral suppression and lipid profiles in HIV-1 patients.
  • What are researchers studying about emtricitabine in hepatitis B trials? In hepatitis B trials, researchers are evaluating emtricitabine's effectiveness in reducing viral load (HBV DNA levels), improving liver function (ALT normalization), and preventing vertical transmission from pregnant women to their newborns. They're also assessing its safety profile and potential for developing drug resistance.
  • How is emtricitabine being investigated for Alzheimer's disease? A clinical trial is exploring the potential of emtricitabine in treating Alzheimer's disease. The study aims to assess its safety and tolerability in patients with mild cognitive impairment or early Alzheimer's disease, and to evaluate its effects on inflammatory biomarkers and cognitive function measures.
  • What are some common outcomes being measured in emtricitabine clinical trials? Common outcomes measured in emtricitabine trials include viral suppression (HIV or HBV DNA levels), changes in CD4+ cell counts for HIV patients, liver function tests for hepatitis B patients, safety and tolerability assessments, and in some cases, cognitive function tests for Alzheimer's disease research. Researchers also monitor for potential side effects and drug resistance.

Ongoing Clinical Trials on Emtricitabine

  • A study of islatravir and ulonivirine for adults with HIV who have not received previous treatment

    Recruiting

    4 1 1
    Investigated drugs:
    France Spain

  • A study testing VH4524184 with emtricitabine and tenofovir alafenamide compared to dolutegravir and lamivudine in adults with HIV-1 who have not received treatment before

    Recruiting

    2 1 1 1
    Investigated drugs:
    Belgium France Germany Italy Poland Portugal +1

  • Study on the Effects and Safety of Ianalumab in Adults with Lupus Nephritis Who Completed Previous Treatment

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Hungary Romania Spain

  • Study on the Effectiveness and Safety of Ianalumab for Patients with Diffuse Cutaneous Systemic Sclerosis

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium France Germany Greece Hungary +4

  • Study Comparing Doravirine and Dolutegravir-Based Treatments for People with HIV-1 Who Have Not Yet Started Therapy

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Long-Term Safety of Ianalumab for Patients with Systemic Lupus Erythematosus

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia France Germany Hungary Italy +5

  • Study on HIV-1 Treatment for Patients New to Therapy: Comparing Doravirine/Islatravir with a Drug Combination

    Not yet recruiting

    3 1 1
    Investigated drugs:
    France Germany Italy The Netherlands Poland Spain

  • Study of Weekly Oral GS-1720 and GS-4182 for People with HIV-1 Who Are Virologically Suppressed

    Not yet recruiting

    4 1 1 1
    Investigated drugs:
    France Germany Italy Poland Spain Sweden

  • Study on Switching HIV Treatment to Doravirine and Islatravir for Patients with HIV-1

    Not yet recruiting

    3 1 1
    Investigated drugs:
    France Germany Italy Spain

  • Phase 3 study of ianalumab plus standard drug combination in adults and adolescents with systemic lupus erythematosus

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia Hungary Poland Portugal Slovakia +1

Glossary

  • Emtricitabine: A nucleoside reverse transcriptase inhibitor used in the treatment of HIV and hepatitis B infections. It works by inhibiting viral replication.
  • Viral suppression: The reduction of virus levels in the body to very low or undetectable levels, often measured by HIV RNA or HBV DNA levels in the blood.
  • HBeAg: Hepatitis B e-antigen, a protein produced by the hepatitis B virus. Its presence in the blood indicates active viral replication.
  • ALT normalization: The return of alanine aminotransferase (ALT) levels to the normal range. ALT is an enzyme that can indicate liver damage when elevated.
  • Vertical transmission: The passage of a disease-causing agent from mother to baby during pregnancy, childbirth, or breastfeeding.
  • Lipidomic profile: A comprehensive analysis of lipid molecules in biological samples, used to study the effects of drugs on lipid metabolism.
  • Mild Cognitive Impairment (MCI): A condition characterized by a slight but noticeable decline in cognitive abilities, often considered an early stage of dementia.
  • CD4+ cell count: A measure of the number of T helper cells in the blood, used to assess the strength of the immune system in HIV patients.
  • Antiretroviral therapy: A combination of medications used to treat HIV infection by suppressing viral replication and slowing the progression of the disease.
  • HBsAg: Hepatitis B surface antigen, a protein on the surface of the hepatitis B virus. Its presence in the blood indicates a current hepatitis B infection.

References

  1. https://clinicaltrials.gov/study/NCT00642291
  2. https://clinicaltrials.gov/study/NCT02327663
  3. https://clinicaltrials.gov/study/NCT02104700
  4. https://clinicaltrials.gov/study/NCT02968576
  5. https://clinicaltrials.gov/study/NCT02547844
  6. https://clinicaltrials.gov/study/NCT02327702
  7. https://clinicaltrials.gov/study/NCT00391638
  8. https://clinicaltrials.gov/study/NCT04500847